retatrutide trial data 24.2% body weight lost at 48 weeks. Not by eating less. By burning more at rest. is a triple agonist: a single synthetic peptide that simultaneously engages three receptors — GLP-1R Retatrutide Results: 28.3% Weight Loss

UK patients interested in access may explore participation in the phase 3 TRIUMPH trials via the NIHR Be Part of Research platform

3163 NAION (visionloss) Allegations A separate proceeding, MDL 3163, addresses claims that GLP1 therapies caused nonarteritic anterior ischemic optic neuropathy (NAION), a condition associated with sudden vision loss

Overall, glutathiones neuroprotective efficacy in the CNS is intricately regulated by enzyme expression, metabolic substrate availability, and regional brain biochemistry, making it a pivotal target for intervention in oxidative stress-related neuropathologies

Ketone bodies inhibit the viability of human neuroblastoma cells